Aytu Biopharma Inc expected to post a loss of 49 cents a share - Earnings Preview

Aytu Biopharma

09/11/2021 03:01

* Aytu Biopharma Inc  AYTU.OQ   AYTU.O  is expected to show a
rise in quarterly revenue when it reports  results on November
10. 
* The Englewood, Colorado-based company is expected to report  a
63.5% increase in revenue to $22.1 million from $13.52 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
​* Refinitiv's mean analyst estimate for Aytu Biopharma Inc is
for a loss of 49 cents per share. For the same quarter last
year, the company reported a loss of 40 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Aytu Biopharma
Inc is $17.5​, about 85.5% above​ its last closing price
of $2.53. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.66       -0.49      -0.75     Missed  -53.1
 Mar. 31 2021  -0.31       -0.31      -1.41     Missed  -347.6
 Dec. 31 2020  -0.38       -0.44      -0.70     Missed  -59.1​
 Sep. 30 2020  -0.55       -0.55      -0.40     Beat    27.3
 ​​Jun.        -0.50       -0.35      -0.20     Beat    42.9
 30 2020                                                
 Mar. 31 2020  -1.91       -2.20      -1.50     Beat    31.8​
 Dec. 31 2019  -2.32       -2.45      -0.10     Beat    95.9
 Sep. 30 2019  -3.00       -2.75      -3.20     Missed  -16.4
 This summary was machine generated November 9 at 03:01 GMT.  All
figures in US dollars unless otherwise stated